$89.60
+0.84 (+0.95%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DXCM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
16 interventional · 19 observational · 4 with posted results
Held by 20 tracked-famous managers (BAILLIE GIFFORD & CO, AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +15 more) · FINRA short interest 3.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 6 sells · government filings 180d: 2 congress / 7 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)NCT07681024observationalEvaluations | — | Not yet recruiting | Device: Dexcom CGM (Continuous Glucose Monitor) | Diabetes | 5,000 | 2030-05-01 | in 1,351 d | 2026-07-02 |
| Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)NCT06483945observationalPatient Reported Outcomes (PROs) | — | Recruiting | Device: Dexcom CGM G6/G6 Pro/G7 | Diabetes | 5,000 | 2028-03-31 | in 590 d | 2024-07-03 |
| Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi ArabiaNCT07603284Change in HbA1cOpen-label · Supportive care | Phase 4 | Active, not recruiting | Device: Real-Time Continuous Glucose Monitoring | Type 2 Diabetes on Insulin | 200 | 2026-11-02 | in 75 d | 2026-05-22 |
| CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on InsulinNCT06601166To assess the benefit on glycemic control and safety from baseline to week 26 using CGM versus RC.Randomized · Open-label · Treatment | Not applicable | Active, not recruiting | Device: CGM | Type 2 Diabetes | 283 | 2026-05-13actual | — | 2026-08-11 |
| Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 SensorNCT07681375Measurement of participant safety while using the DexBasal Study SystemOpen-label · Device feasibility | Phase 1 | Active, not recruiting | Drug: Basal insulin · Device: Dexcom Continuous Glucose Monitoring (CGM) | Type 2 Diabetes | 45 | 2026-01-16actual | — | 2026-07-02 |
| Continuous Monitoring and Control of HypoglycemiaNCT03340831observationalChange in hypoglycemic events | — | Unknown status | Device: Continuous Glucose Monitoring (CGM) | Diabetes | 1,388 | 2023-12-30 | — | 2021-09-21 |
| Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for DysglycemiaNCT05746286Reduce amount of ER readmission in first 30 days after dischargeOpen-label · Other | Not applicable | Completed | Device: Dexcom G6 CGM | Dysglycemia | 40 | 2023-11-29actual | — | 2025-11-25 |
| Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes MellitusNCT04905628observationalDexcom Continuous Glucose Monitoring (CGM) System Performance | — | Unknown status | Device: Dexcom CGM System | Diabetes Mellitus | 100 | 2022-03-31 | — | 2022-02-21 |
| Prediabetes and Type 2 Diabetes Data Collection StudyNCT04503239observationalCollect Device Data - CGM | — | Unknown status | Device: G6 | Diabetes Mellitus, Type 2, Pre-diabetes | 306 | 2022-02-27 | — | 2021-10-05 |
| Assessing Non-adjunctive CGM Safety at Home and in New MarketsNCT04585139HbA1cRandomized · Open-label · Supportive care | Not applicable | Completed | Device: Phase 1- Introduction to Dexcom G6 CGM | Diabetes Mellitus | 85 | 2022-02-07actual | — | 2022-08-01 |
| Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System in Non-Critically Ill Patients in the Inpatient SettingNCT04879693System PerformanceOpen-label · Other | Not applicable | Unknown status | Device: Continuous Glucose Monitoring System | Patients Needing Glucose Control | 250 | Dec 2021 | — | 2021-05-10 |
| Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) SystemNCT04794478Dexcom Continuous Glucose Monitoring System PerformanceOpen-label · Other | Not applicable | Completed | Device: Dexcom Continuous Glucose Monitoring System | Diabetes Mellitus | 482 | 2021-08-09actual | — | 2022-02-18 |
| Evaluation of Modified Adhesives With Dexcom G6 SensorNCT04840446observationalAdhesiveness and survivability of the adhesives | — | Completed | Device: Dexcom Continuous Glucose Monitoring System | Diabetes | 80 | 2021-03-16actual | — | 2021-04-12 |
| Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)NCT03566693Phase 1: Change in HbA1cRandomized · Open-label · Treatment | Not applicable | Completed | Device: Dexcom G6 CGM System, Blood glucose meter | Diabetes Mellitus, Type 2 | 176 | 2021-01-04actual | — | 2021-04-21 |
| Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) SystemNCT04645641System PerformanceOpen-label · Other | Not applicable | Unknown status | Device: Continuous Glucose Monitoring System | Diabetes Mellitus | 150 | Dec 2020 | — | 2020-11-27 |
| Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)NCT03620357HbA1cRandomized · Open-label · Treatment | Not applicable | Completed | Device: CGM, SMBG | Diabetes Mellitus, Type 2 | 72 | 2020-05-27actual | — | 2021-03-22 |
| Glucose Risk Assessment in Employer PopulationsNCT04529824observationalDiabetes Status | — | Completed | Device: Dexcom G6 Continuous Glucose Monitor (CGM) System | Diabetes, Pre-diabetes, Glucose Intolerance | 207 | 2019-07-22actual | — | 2023-02-15 |
| Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes MellitusNCT03935191observationalDexcom G6 CGM Accuracy | — | Unknown status | Device: Dexcom CGM System | Diabetes | 60 | 2019-05-31 | — | 2019-05-02 |
| Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring SystemNCT02880267Proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a proportion of blood glucose values, compared between CGM and a lab glucose analyzer matched to an accuracy measurement of %20/20 mg/dLOpen-label · Other | Not applicable | Completed | Device: CGM | Diabetes Mellitus | 304 | Jul 2017actual | — | 2018-12-31 |
| Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent SensorNCT03087877Interference Effect for the G6 CGMOpen-label · Other | Not applicable | Completed | Device: Acetaminophen Challenge (G6 CGM) | Diabetes Mellitus | 70 | 2017-03-04actual | — | 2018-12-31 |
| Multiple Daily Injections and Continuous Glucose Monitoring in DiabetesNCT02282397Phase 1 (T1DM) - A1CRandomized · Open-label · Diagnostic | Not applicable | Completed | Device: Continuous Glucose Monitor | Diabetes Mellitus | 316 | Nov 2016actual | — | 2017-05-15 |
| G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor ApplicatorNCT02696252observationalproportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL | — | Completed | — | Diabetes Mellitus | 97 | Apr 2016actual | — | 2016-04-14 |
| Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified AlgorithmNCT02087995results2017-08-24The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement.Open-label · Other | Not applicable | Completed | Device: Continuous Glucose Monitoring | Diabetes Mellitus | 51 | Mar 2014actual | — | 2017-08-24 |
| Long-term Use: CGM System Assessment in Adult Athletes With Diabetes MellitusNCT01627184observationalGlycemic Control during Exercise | — | Completed | Device: Dexcom G4 CGM System | Diabetes Mellitus | 13 | Jan 2013actual | — | 2015-02-12 |
| Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 SystemNCT01627210observationalEvaluate the Dexcom G4 system utility and usability during home use. | — | Completed | — | Diabetes Mellitus | 60 | Dec 2012actual | — | 2013-02-12 |
| Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes MellitusNCT01667185observationalSystem Performance Effectiveness | — | Completed | — | Pediatric Subjects With Diabetes Mellitus | 176 | Dec 2012actual | — | 2013-02-08 |
| Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in PediatricsNCT02363907results2017-07-27observationalPoint Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device | — | Completed | — | Diabetes Mellitus | 30 | Oct 2012actual | — | 2017-07-27 |
| Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring SystemNCT01514292results2015-10-05CGM Relative Differences to Laboratory ReferenceOpen-label · Treatment | Not applicable | Completed | Device: Continuous Glucose Monitoring of glucose levels (Dexcom) | Diabetes | 72 | Feb 2012actual | — | 2015-10-05 |
| Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring SystemNCT01514305observationalAbsolute Relative Difference (%) to Reference Standard | — | Completed | — | Diabetes | 21 | Dec 2011actual | — | 2012-01-23 |
| Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes MellitusNCT01185496observational | — | Completed | — | Diabetes Mellitus | 64 | Oct 2010actual | — | 2011-06-13 |
| Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring SystemNCT01111370results2017-03-27the Proportion of G4 CGM System in Agreement With the Reference StandardOpen-label · Other | Not applicable | Completed | Device: DexCom™ G4 Continuous Glucose Monitoring System | Diabetes Mellitus | 60 | Apr 2010actual | — | 2017-03-27 |
| Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic SettingNCT00925080observationalIVBG System accuracy will primarily be assessed relative to ISO 15197 criteria (i.e., within ±15 mg/dL at YSI glucose levels < 75 mg/dL, and within ±20% at YSI glucose levels >75 mg/dL). | — | Completed | Device: IVBG | Diabetes, Hyperglycemia | 50 | Jul 2009actual | — | 2010-02-03 |
| Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)NCT00939289observationalCGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics | — | Completed | Device: Continuous Glucose Monitoring | Type 1 Diabetes Mellitus | 14 | Aug 2008actual | — | 2010-02-03 |
| Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring SystemNCT00722241observationalSEVEN.2 System accuracy as compared to Yellow Springs Instrument (YSI) venous blood glucose measurements | — | Completed | — | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 53 | Jun 2008actual | — | 2008-07-25 |
| Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) TherapyNCT01104142observational | — | Completed | Device: CGM | Type 1 Diabetes Mellitus | 120 | — | — | 2010-04-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19